Search Within

Malin Lisa Hultcrantz

Formats
  1. Meeting Abstract (171)
  2. Journal Article (68)
  3. Research Letter (9)
  4. Guidelines (6)
  5. Review (3)
  6. Correspondence (2)
  7. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (260)
  2. Department of Medicine (260)
  3. Hematologic Malignancies, Division of (260)
  4. Myeloma (260)
  5. Sloan Kettering Institute Postdocs (260)
  6. Hematologic Malignancies Research (179)

More Groups

People
  1. Sham Mailankody (148)
  2. Neha Korde (145)
  3. Alexander Lesokhin (140)
  4. Hani Hassoun (135)
  5. Urvi Shah (125)
  6. Heather Landau (119)

More People

Years
  1. 2025 (8)
  2. 2024 (39)
  3. 2023 (51)
  4. 2022 (52)
  5. 2021 (30)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (50)
  3. Journal of Clinical Oncology (17)
  4. Blood Cancer Journal (13)
  5. Haematologica (10)
  6. Blood Advances (6)

More Publications

Publishers
  1. American Society of Hematology (103)
  2. Elsevier Inc. (55)
  3. Nature Publishing Group (21)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (10)
  6. American Association for Cancer Research (6)

More Publishers

Results (260)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Initial whole genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
    Meeting Abstract

    Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; Iacobuzio-Donahue, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Multiple myeloma, version 3.2021: NCCN Clinical Practice Guidelines in Oncology
    Guidelines

    Kumar, S. K.; Callander, N. S.; Adekola, K.; Anderson, L.; Baljevic, M.; Campagnaro, E.; Castillo, J. J.; Chandler, J. C.; Costello, C.; Efebera, Y.; more...
    Journal of the National Comprehensive Cancer Network (2020)

    Fulltext@MSK | Save
  • DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Meeting Abstract

    Kortüm, M.; Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N.; Suvannasankha, A.; Badros, A.; Libby, E.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Meeting Abstract

    Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N. S.; Suvannasankha, A.; Badros, A.; Libby, E. N.; Trudel, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors and immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs), including subgroups with renal impairment (RI) and high-risk (HR) cytogenetics
    Meeting Abstract

    Lonial, S.; Lee, H. C.; Badros, A.; Trudel, S.; Nooka, A. K.; Chari, A.; Abdallah, A. O.; Callander, N. S.; Sborov, D. W.; Suvannasankha, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma
    Journal Article

    Bal, S.; Landau, H. J.; Shah, G. L.; Scordo, M.; Dahi, P.; Lahoud, O. B.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lendvai, N.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Accelerated single cell seeding in relapsed multiple myeloma
    Journal Article

    Landau, H. J.; Yellapantula, V.; Diamond, B. T.; Rustad, E. H.; Maclachlan, K. H.; Gundem, G.; Medina-Martinez, J.; Arango Ossa, J.; Levine, M. F.; Zhou, Y.; more...
    Nature Communications (2020)

    Fulltext@MSK | Save
  • Baseline VDJ clonotype detection using a targeted sequencing NGS assay: Allowing for subsequent MRD assessment
    Research Letter

    Hultcrantz, M.; Rustad, E. H.; Yellapantula, V.; Arcila, M.; Ho, C.; Syed, M. H.; Papaemmanuil, E.; Zhang, Y.; Maura, F.; Landgren, O.
    Blood Cancer Journal (2020)

    Fulltext@MSK | Save